Abstract

BackgroundThe relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM.MethodsCirculating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively.ResultsThe median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e′ (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (β = 0.89, P < 0.01) and worsening of average E/e′ (β = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16–6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease.ConclusionCirculating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD.

Highlights

  • The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, with conflicting results

  • Previous studies have examined the association between circulating AFABP level with left ventricular (LV) remodelling and diastolic dysfunction in various groups of patients [19,20,21, 33], most were of cross-sectional study design and showed conflicting results

  • We demonstrated that baseline circulating AFABP level was independently associated with increase in LV mass and worsening of average E/e′ ratio over a 28-month follow-up period, which provided firm evidence that an elevated circulating AFABP level correlated with cross-sectional assessments of LV mass and average E/e′ ratio, but could predict a further deterioration of LV remodelling and diastolic function in Type 2 diabetes mellitus (T2DM) patients

Read more

Summary

Introduction

The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, with conflicting results. Type 2 diabetes mellitus (T2DM) is associ‐ ated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. We investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction independent of underlying coronary artery disease (CAD) [1,2,3], and contributes to the development of major adverse cardiovascular events (MACE) [4]. Adipocyte fatty acid-binding protein (AFABP) is a lipid chaperone protein mainly expressed in adipocytes and macrophages. It is secreted by adipocytes and circulates in the bloodstream [7]. Raised circulating AFABP level has been shown to associate with MACE in patients with CAD [13], as well as aortic arterial stiffness and cardiovascular mortality in patients with T2DM [14,15,16]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call